AstraZeneca has entered into an agreement with TerSera Therapeutics for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada, an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
AstraZeneca will receive $250 million upfront, sales-related income through milestones totalling up to $70 million and recurring quarterly sales-based payments at mid-teen percent of Product Sales.
AstraZeneca will manufacture and supply Zoladex to TerSera
Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy at AstraZeneca said that this agreement allows AstraZeneca to retain a share of the value of Zoladex in the US and Canada, while concentrating our resources on our innovative New Oncology medicines.
Zoladex was first approved in the US and Canada in 1989. Product Sales for Zoladex were $69 million in the US and Canada.